All News about Genmab A/S ADR
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via Benzinga
![](https://mms.businesswire.com/media/20240422914519/en/2105097/22/GenmabLogo.jpg)
![](https://mms.businesswire.com/media/20240415775924/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Via Chartmill
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://www.investors.com/wp-content/uploads/2024/04/TECH1_radiopharma_042624_shutter.jpg)
![](https://cdn.benzinga.com/files/profoundbio-0408-01.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2024/04/Stock-genmab-01-shutt.jpg)
![](https://mms.businesswire.com/media/20240402203285/en/2087648/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Analyst Ratings For Genmab
March 26, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
4 Analysts Assess Genmab: What You Need To Know
February 20, 2024
Via Benzinga
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://mms.businesswire.com/media/20240227092202/en/2045857/5/Genmab_Logo_Color_RGB.jpg)
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For Genmab
February 13, 2024
Via Benzinga
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Cracking The Code: Understanding Analyst Reviews For Genmab
January 29, 2024
Via Benzinga
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://mms.businesswire.com/media/20240202549142/en/2018874/22/GenmabLogo.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/Gavel-law-Image-by-Okan-Caliskan-from-Pi_2.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20240105049976/en/1989817/5/Genmab_Logo_Color_RGB.jpg)
![](https://mms.businesswire.com/media/20240109858951/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://cdn.benzinga.com/files/images/story/2023/12/12/oracle_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20231208348497/en/1964677/5/Genmab_Logo_Color_RGB.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.